Biovance Capital

What Biovance Capital does

Biovance Capital is a Lisbon-based venture capital firm founded in 2024 that manages Biovance Capital Fund I, a €57 million (approaching a €60 million target) biotech-focused fund. The firm invests in seed and Series A rounds of early-stage biopharma companies across Europe, with special focus on Southern Europe (Portugal, Spain, and Italy), deploying ticket sizes ranging from €1.5 to €6 million per company. Biovance Capital is the first healthcare-specialized VC fund in Portugal and the first Portuguese life sciences VC fund to receive investment from the European Investment Fund. The firm's product is its fund vehicle, which supports the development of transformational therapies across all modalities and therapeutic areas.

The investment team is composed of MD/PhD-credentialed professionals educated at Harvard Medical School, MIT, and Imperial College, supported by a Scientific Advisory Board. Key personnel include Managing Partner Ricardo Perdigão Henriques (PhD; previously at Portugal Ventures and Bionova Capital/Hovione), General Partner João Incio (MD, PhD), and Principal André Albergaria (PhD; 20+ years of industry-academia collaboration at i3S). The team's track record includes a successful exit in the cancer space with potential returns exceeding €1 billion. The firm operates from offices in Lisbon (headquarters) and Porto (Matosinhos), with a core team of approximately 10 individuals plus external consultants.

Biovance Capital follows a standard VC economic model: management fees (typically 2% annually on committed capital) cover operational costs during the investment period, while carried interest (typically 20% of profits from successful exits) represents the primary upside driver. The fund is capitalized by institutional investors including the European Investment Fund, BIAL (Portugal's largest pharmaceutical company), Banco Português de Fomento, the European Commission (via Portugal Tech and InvestEU programmes), Caixa Capital, Ageas Pensions, EDP Pension Fund, and private investors from the USA and Europe. The firm does not charge portfolio companies directly; instead, it generates returns through equity participation and supports portfolio companies through board representation, syndication with co-investors (OrbiMed, Torrey Pines, Kurma Partners), and access to its scientific network.

Name

Biovance Capital

Legal name

Biovance Capital Partners, Sociedade de Capital de Risco, S.A.

Website

https://biovancecapital.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Biovance Capital is a Lisbon-based venture capital firm managing a €57 million biotech-focused fund that invests in seed and Series A rounds of early-stage biopharma companies across Europe, with a primary focus on Southern Europe (Portugal, Spain, Italy).

Ownership category

akta.pro rank

Product category

Venture Capital / Life Sciences Investment Management

NAICS

Portfolio Management and Investment Advice (523940), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Renewables & Energy Transition Funds (Solar, Wind, Hydrogen, CCUS) (FSANAEAD)

Keywords

• Venture capital funding
• Early-stage biotech investing
• Biopharma seed rounds
• Series A biotech
• Life sciences fund

Headquarters

HQ city

Lisbon

HQ country

Portugal

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Fund Management Fees: VC funds typically charge management fees on committed capital, usually 2% annually, during the investment period. This provides regular revenue to cover operational costs.
2. Carried Interest (Carry): The primary revenue driver for VC funds. Biovance Capital earns a percentage of profits (typically 20%) from successful portfolio company exits through M&A or IPO events. This aligns fund manager interests with investor returns.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Biovance Capital manages Biovance Capital Fund I, a Portugal-domiciled venture capital fund of approximately €57M (target €60M) that invests in disruptive, early-stage biopharma companies across Europe with a special focus on Southern Europe. The fund provides seed and Series A equity capital in tickets ranging from €1.5 to €6 million, and supplements the investment with strategic board participation, scientific due diligence, and access to a European network of research institutes, incubators, and accelerators. The firm brings co-investors to portfolio rounds to add value and mitigate risk.

Product overview

Biovance Capital is a venture capital firm operating as a single-product company offering one fund vehicle: Biovance Capital Fund I. This fund is a €57 million (approaching €60 million maximum size) biotech-focused VC fund that provides capital and support to early-stage drug development companies across Europe. The fund is backed by the European Investment Fund, BIAL Pharma, Banco Português de Fomento, the European Commission (Portugal Tech and InvestEU programmes), and private investors including Caixa Capital, Ageas Pensions, and EDP Pension Fund.

Differentiator

Problem solved

Functional benefit

Products and services

• Biovance Capital Fund I Approximately €57 million (target €60M) venture capital fund investing in disruptive, early-stage biopharma companies across Europe with special focus on Portugal and Southern Europe. Targets seed and Series A rounds with ticket sizes ranging from €1.5 to €6 million, supporting the development of transformational therapies across all modalities and therapeutic areas, with co-investors brought in to add value and mitigate risk.

Quantifiable outcome

• Expected to back approximately a dozen biotech startups over next five years
• +1 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Five partnerships are on record, tiered core and major.

• Instituto de Investigação e Inovação em Saúde (i3S)coreStrategic or Co-development PartnerPartnership with i3S, Portugal's largest health research institute, to support the development and spin-out of exceptional biomedical research from Portugal onto the global stage.
• EIT HealthmajorStrategic or Co-development PartnerEuropean network of health innovation supported by the European Institute of Innovation and Technology, providing access to ecosystem resources and potential investment opportunities.
• Universidade de CoimbramajorStrategic or Co-development PartnerPartnership with Universidade de Coimbra, which is developing a €100-150 million Life Science Park project, providing access to academic research and technology transfer opportunities.
• EIC Scaling ClubmajorStrategic or Co-development PartnerBiovance Capital is a partner in the EIC Scaling Club, working with other European biotech VCs to address the investment gap where the US commands 80% of global biotech funding. General Partner João Incio contributed to the Club's market roadmap report.
• EU Life Sciences ESG Knowledge ProjectmajorStrategic or Co-development PartnerBiovance Capital joined this initiative coordinated by Grant Thornton's Impact House with 25 leading European Life Science VC firms to harmonize ESG approaches and create unified frameworks for sustainability measurement and reporting.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Andera Partners: European life sciences-dedicated investment firm with active biotech venture and growth strategies. Comparable as a healthcare-focused VC manager targeting European early-stage biotech companies.
• Kurma Partners: French biotech-focused venture capital firm that co-led the €17M seed round of Laigo Bio alongside Biovance Capital. Directly comparable as a European early-stage healthcare specialist investing at similar ticket sizes in drug development platforms.
• Forbion: Leading European biotech VC firm investing across seed, Series A and later stages in drug development companies. Closely comparable to Biovance in therapeutic focus and stage, though at materially larger fund size.
• Sofinnova Partners: One of Europe's largest dedicated life sciences venture capital firms, with deep exposure to early-stage biotech and therapeutic platforms. Comparable business model of backing transformational therapies from seed through clinical milestones.
• Torrey Pines Investment: San Diego-based specialty life sciences investment firm active since 2002 in early- to development-stage breakthrough medicines. Co-invested with Biovance Capital in Mondego Bio's Series A, making it a direct co-investment peer.
• HealthCap: Swedish-based European venture capital firm dedicated to life sciences, investing across biotech and medtech from early to late stages. Comparable as a Nordic/European biotech VC with similar stage and therapeutic focus.

Broad incumbents

• EQT Life Sciences: Pan-European life sciences investor (formerly LSP) operating venture and growth strategies across healthcare and biotech. Overlaps with Biovance in European biotech investing but at a much larger platform scale with broader mandate.
• OrbiMed: Global healthcare investment firm with over $17B AUM investing across public and private healthcare. Co-invested in Mondego Bio alongside Biovance, marking OrbiMed's first investment in Southern Europe — a much larger incumbent now operating in Biovance's geography.
• LSP (Life Sciences Partners) merged into EQT Life Sciences: Long-established European life sciences VC manager (now part of EQT), investing across all stages of biotech and medtech. Functions as a broader incumbent in the same European healthcare VC category.

Regional players

• Portugal Ventures: Portuguese venture capital firm where Biovance's Managing Partner Ricardo Perdigão Henriques previously worked. Operates as a broader regional VC across sectors in Portugal, overlapping in geography but not healthcare-specialised.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biovance

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biovance Capital